Business Context and Reporting Period
This Form 8-K Current Report from Altimmune, Inc. (ALT) is dated November 30, 2023. The filing serves as a Regulation FD disclosure and announcement of other events regarding the topline results of the Company's 48-week MOMENTUM Phase 2 obesity trial for its investigational drug, pemvidutide.
Key Financial Metrics
This filing is a clinical trial update and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Clinical Results
The primary material event is the announcement of efficacy and safety data from the MOMENTUM Phase 2 trial involving 391 subjects with obesity or overweight and at least one co-morbidity (non-diabetic). Subjects were randomized to receive placebo or weekly doses of pemvidutide (1.2 mg, 1.8 mg, or 2.4 mg) for 48 weeks.
Efficacy Findings (Week 48)
- Mean Weight Loss: Placebo (-2.2%), 1.2 mg (-10.3%), 1.8 mg (-11.2%), and 2.4 mg (-15.6%).
- Responder Rates (2.4 mg dose): 83.9% achieved ≥5% weight loss, 71.4% achieved ≥10%, 51.8% achieved ≥15%, and 32.1% achieved ≥20%.
- Cardiometabolic Improvements: Robust reductions in serum lipids (Total cholesterol, LDL, Triglycerides) and improvements in blood pressure were observed. Glucose homeostasis was maintained with no significant changes in fasting glucose or HbA1c.
Safety and Tolerability
- Adverse Events (AEs): Nausea and vomiting were the most common AEs, predominantly mild to moderate. Gastrointestinal AEs increased with dose.
- Discontinuations: Rates of AEs leading to discontinuation were 6.2% (placebo), 5.1% (1.2 mg), 19.2% (1.8 mg), and 19.6% (2.4 mg). Most discontinuations in treatment groups occurred within the first 16 weeks.
- Cardiac Safety: No Major Adverse Cardiac Events (MACE) were observed. There were no imbalances in cardiac events, arrhythmias, or clinically meaningful increases in heart rate across groups.
- Serious Adverse Events (SAEs): Only one drug-related SAE (vomiting) occurred in the 2.4 mg group (1.0%).
Guidance, Outlook, and Management Commentary
Management indicated a near-linear trajectory of continued weight loss on the 2.4 mg dose at the end of treatment. The Company scheduled a conference call and webcast for December 1, 2023, to discuss these results. No specific financial guidance or future operational milestones beyond the trial results were provided in this filing.
Investor Verification Checklist
- Verify the statistical significance of the weight loss data (indicated by asterisks in the filing) against the placebo group.
- Review the full safety profile regarding gastrointestinal adverse events and their impact on long-term patient retention.
- Confirm the timeline for potential Phase 3 trial initiation based on these Phase 2 results.
- Check subsequent filings for any updates on the Company's cash position, as this 8-K does not report financial liquidity.
- Monitor the conference call presentation (Exhibit 99.2) for details on the mechanism of action and competitive landscape.